Dioxidilar solution for intracavity and external application. 5mg / ml, # 10

For intravenous administration: septic conditions (including in patients with burn disease); purulent meningitis; purulent-inflammatory processes with symptoms of generalization.

For intracavitary administration: purulent processes in the chest and abdominal cavity, incl. purulent pleurisy; empyema of the pleura; peritonitis; cystitis; empyema of the gallbladder; prevention of infectious complications after bladder catheterization.

For external, local use: wound and burn infection (superficial and deep purulent wounds of various localization, long-term non-healing wounds and trophic ulcers, phlegmons of soft tissues, infected burns, purulent wounds in osteomyelitis); wounds with deep purulent cavities (abscess of the lungs, abscesses of soft tissues, phlegmon of pelvic tissue, postoperative wounds of the urinary and biliary tract, purulent mastitis); pustular skin diseases.

Intravenous drip. In severe septic conditions, the maximum single dose is 300 mg, the daily dose is 600 mg.

Intracavitary administration: 10-50 ml of a 1% solution is injected through a drainage tube, catheter or syringe.

Outwardly, on the wound surface, previously cleaned of purulent-necrotic masses, napkins moistened with 1% solution are applied daily or every other day, depending on the condition of the burn wound and the course of the wound process. Deep wounds are tamponed or irrigated with 0.5% solution. The maximum daily dose is 2.5 g. The duration of treatment is up to 3 weeks.

Solution for intracavitary and external use, greenish-yellow, transparent.

Note: during storage, crystals of hydroxymethylquinoxalindioxide (dioxidine) may precipitate in ampoules with a solution. In case of precipitation of crystals of hydroxymethylquinoxalindioxide (dioxidine) during storage, they are dissolved by heating the ampoules with the solution in a boiling water bath with shaking until the crystals are completely dissolved (clear solution). If, when cooled to 36-38 ? C, the crystals do not fall out again, the drug is suitable for use.

1 ml hydroxymethylquinoxaline dioxide 5 mg

Excipients: water d / i - up to 1 ml.

• Adrenal insufficiency (including history);

• pregnancy;

• lactation period (breastfeeding);

• children under 18 years of age;

• hypersensitivity to the active substance.

pharmachologic effect

Broad-spectrum antimicrobial agent, quinoxaline derivative. It has a bactericidal effect.

Active against Proteus vulgaris, Pseudomonas aeruginosa, Friedlander's bacillus, Escherichia coli, Shigella dysenteria, Shigella flexneri, Shigella boydii, Shigella sonnei, Salmonella spp., Staphylococcus spp., Streptococcus spp., Pathogenic anaerobes. Acts on strains of bacteria that are resistant to other antimicrobial drugs, including antibiotics. Does not have a local irritating effect. The development of drug resistance of bacteria is possible.

When administered intravenously, it is characterized by a small therapeutic breadth, and therefore it is necessary to strictly adhere to the recommended doses.

Treatment of burns and purulent-necrotic wounds promotes faster cleaning of the wound surface, stimulates reparative regeneration and marginal epithelization, and has a beneficial effect on the course of the wound process.

Experimental studies have demonstrated the presence of teratogenic, embryotoxic and mutagenic effects.

Pharmacokinetics

After intravenous administration, the therapeutic concentration in the blood is maintained for 4-6 hours. The time to reach Cmax in the blood is 1-2 hours after a single injection. It penetrates well and quickly into all organs and tissues, and is excreted by the kidneys. With repeated administrations, it does not cumulate.

Side effect

Possibly: allergic reactions.

After intravenous and intracavitary administration - headache, chills, hyperthermia, nausea, vomiting, diarrhea, muscle twitching.

Local reactions: peri-wound dermatitis.

Application during pregnancy and lactation

Use during pregnancy and lactation (breastfeeding) is contraindicated.

Application for impaired renal function

Use with caution in patients with renal impairment.

Application in children

The drug is contraindicated for use in children and adolescents under the age of 18 years.

special instructions

Use with caution in patients with renal impairment.

With chronic renal failure, the dose is reduced. Prescribed only if other antimicrobial drugs are ineffective.